The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Drug maker Gilead (GILD) is rallying 7.5% after the company reported stronger-than-expected fourth-quarter results and ...

Health care providers at the John B. Amos Cancer Center in Columbus, Georgia are among the first in the state to administer a new therapy for cancer treatment. Phenix City, Alabama resident Susan ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.

The FDA reviews drug approval decisions that are expected in March 2025. The FDA is reviewing the application for bentracimab for use as a ticagrelor reversal agent in patients with uncontrolled ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Apogee Therapeutics (NASDAQ:APGE – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Guggenheim in a ...

While flu is most serious for older Americans and individuals with certain chronic conditions, it can affect people of all ...